Latest publications

Lund T, Gundesen MT, Juul Vangsted A, Helleberg C, Haukås E, Silkjær T, Asmussen JT, Manuela Teodorescu E, Amdi Jensen B, Schmidt Slørdahl T, Nahi H, Waage A, Abildgaard N, Schjesvold F, Nordic Myeloma Study Group (2024)
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Blood Cancer J, 14 (1), 65
DOI 10.1038/s41408-024-01046-2, PubMed 38622134

Nørgaard JN, Moore KLF, Slørdahl TS, Vik A, Tvedt THA, Schjesvold F (2024)
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
Blood Cancer J, 14 (1), 60
DOI 10.1038/s41408-024-01047-1, PubMed 38594252

Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Säily M, Uttervall K, Putkonen M, Carlson K, Haukas E, Sankelo M, Szatkowski D, Hansson M, Marttila A, Svensson R, Axelsson P, Lauri B, Mikkola M, Karlsson C, Abelsson J, Ahlstrand E, Sikiö A, Klimkowska M, Matuzeviciene R, Fenstad MH et al. (2024)
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Cancers (Basel), 16 (5)
DOI 10.3390/cancers16051024, PubMed 38473382